Cutaneous metastasis of rectal adenocarcinoma is a rare event occurring in fewer than 4% of all patients with rectal cancer. When present, it typically signifies disseminated disease with a poor ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

From there, metastatic cells travel even further back in time—back to a point before they're locked into becoming intestinal ...

as they promote the growth and metastasis of melanoma. The research is published in Nature Communications. Studies have shown ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...

Melanoma is a type of skin cancer. When it spreads to other places in your body, it's called metastatic, or advanced. If you have fair skin or you’ve spent lots of time in the sun, it’s a ...

FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not ...

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.

Cutaneous metastases from rectal adenocarcinoma can reach the skin via four main routes (Braverman, 1981; Resnik, 1999). Most commonly, tumor cells spread to the skin via lymphatic and/or ...

as they promote the growth and metastasis of melanoma. Studies have shown that certain activity-boosting mutations in the ion channel TPC2 are associated with fair skin, blond hair, and albinism.